Table 3.
Daily phenprocoumon doses and phenprocoumon plasma concentrations according to genotypes, demographic parameters, lifestyle factors and concomitant medication. Values are given as median (interquartile range)
| Parameter | n | Daily phenprocoumon dose, mg | p value* | Phenprocoumon concentration, mg/l | p value* |
|---|---|---|---|---|---|
| VKORC1 c.-1639 | |||||
| GG | 30 | 2.79 (2.14–3.70) | 2.29 (1.98–2.91) | ||
| GA | 33 | 1.93 (1.50–2.47) | 1.85 (1.53–2.28) | ||
| AA | 12 | 1.40 (1.18–1.66) | <0.001 | 1.05 (0.86–1.24) | <0.001 |
| CYP2C9 | |||||
| *1/*1 | 48 | 2.14 (1.50–2.79) | 1.84 (1.27–2.27) | ||
| *1/*2 | 18 | 1.71 (1.50–2.47) | 2.02 (1.60–2.63) | ||
| *1/*3 | 8 | 2.25 (1.64–3.81) | 2.00 (1.83–3.04) | ||
| *2/*2 | 0 | – | – | ||
| *2/*3 | 1 | 2.14 (2.14) | 5.1 (5.1) | ||
| *3/*3 | 0 | – | 0.795 | – | <0.001 |
| CYP4F2 c.1297 | |||||
| GG | 37 | 2.36 (1.71–3.11) | 2.06 (1.51–2.56) | ||
| GA | 36 | 1.82 (1.50–2.52) | 1.84 (1.52–2.26) | ||
| AA | 2 | 1.82 (1.50–1.82) | 0.221 | 1.86 (1.45–1.86) | 0.472 |
| CALU c.*4 | |||||
| AA | 28 | 2.14 (1.55–2.79) | 1.92 (1.27–2.26) | ||
| AG | 41 | 2.14 (1.50–2.79) | 1.99 (1.53–2.44) | ||
| GG | 6 | 2.90 (2.17–3.75) | 0.197 | 1.90 (1.54–3.25) | 0.735 |
| EPHX1 c.337 | |||||
| TT | 35 | 2.25 (1.71–3.00) | 1.92 (1.56–2.30) | ||
| TC | 29 | 2.14 (1.56–2.79) | 1.99 (1.49–2.49) | ||
| CC | 11 | 1.71 (1.39–2.14) | 0.033 | 1.62 (1.17–2.48) | 0.767 |
| F7 c.-402 | |||||
| GG | 53 | 2.14 (1.5–2.79) | 1.87 (1.52–2.44) | ||
| GA | 20 | 2.14 (1.55–3.16) | 1.93 (1.33–2.30) | ||
| AA | 2 | 2.04 (1.71–2.04) | 0.891 | 1.92 (1.81–1.92) | 0.870 |
| F7 c.-401 | |||||
| GG | 50 | 2.20 (1.66–3.05) | 1.91 (1.53–2.42) | ||
| GT | 25 | 1.93 (1.50–2.47) | 1.95 (1.49–2.32) | ||
| TT | 0 | – | 0.193 | – | 0.367 |
| GGCX c.214+597 | |||||
| GG | 26 | 2.14 (1.66–2.63) | 2.01 (1.55–2.34) | ||
| GA | 34 | 2.14 (1.50–2.84) | 1.93 (1.50–2.52) | ||
| AA | 15 | 2.25 (1.61–3.21) | 0.835 | 1.82 (1.47–2.30) | 0.808 |
| PROC c.-228 | |||||
| CC | 32 | 2.36 (1.93–3.16) | 2.09 (1.66–2.48) | ||
| CT | 36 | 1.71 (1.50–2.79) | 1.86 (1.39–2.17) | ||
| TT | 7 | 1.50 (1.18–2.14) | 0.018 | 1.61 (0.74–2.64) | 0.275 |
| PROC c.-215 | |||||
| GG | 16 | 2.79 (1.77–3.56) | 1.93 (1.58–2.54) | ||
| GA | 37 | 2.14 (1.50–2.68) | 1.95 (1.50–2.38) | ||
| AA | 22 | 1.71 (1.50–2.47) | 0.072 | 1.90 (1.48–2.40) | 0.939 |
| Sex | |||||
| Female | 38 | 2.14 (1.71–3.00) | 2.09 (1.82–2.65) | ||
| Male | 37 | 2.14 (1.50–2.79) | 0.735 | 1.65 (1.29–2.22) | 0.008 |
| Alcohol consumption | |||||
| Patients not reporting alcohol habits | 19 | 2.14 (1.50–2.36) | 1.61 (1.17–2.15) | ||
| 0–1 drinks per week | 22 | 2.04 (1.47–3.11) | 1.90 (1.50–2.48) | ||
| 2–5 drinks per week | 22 | 2.68 (1.88–3.40) | 2.29 (1.76–3.09) | ||
| >5 drinks per week | 12 | 1.82 (1.55–2.33) | 0.060 | 1.72 (1.49–2.07) | 0.020 |
| Nicotine habits | |||||
| Smoker | 9 | 1.93 (1.50–3.00) | 1.53 (1.13–2.13) | ||
| Non-smoker | 65 | 2.14 (1.56–2.79) | 0.485 | 1.95 (1.58–2.39) | 0.124 |
| Concomitant medication | |||||
| No concomitant drugs | 21 | 2.14 (1.71–3.16) | 2.15 (1.50–2.94) | ||
| Drugs not known to interfere with phenprocoumon | 10 | 2.47 (1.66–3.05) | 1.63 (1.50–2.24) | ||
| Potentiating drugs, no attenuating drugs | 28 | 1.82 (1.50–2.52) | 1.92 (1.19–2.30) | ||
| Attenuating drugs, no potentiating drugs | 2 | 1.77 (1.39–1.77) | 2.06 (1.85–2.06) | ||
| Both potentiating and attenuating drugs | 14 | 2.31 (1.66–3.54) | 0.380 | 1.93 (1.72–2.47) | 0.346 |
*p values for the overall comparison among the subgroups